Corcept Therapeutics Incorporated
CORT
$115.70
$1.721.51%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 830.81M | 769.10M | 761.41M | 741.17M | 716.08M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 830.81M | 769.10M | 761.41M | 741.17M | 716.08M |
| Cost of Revenue | 14.09M | 13.46M | 12.98M | 13.39M | 11.66M |
| Gross Profit | 816.73M | 755.64M | 748.43M | 727.78M | 704.42M |
| SG&A Expenses | 556.47M | 503.42M | 448.73M | 401.86M | 351.63M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 824.41M | 777.32M | 716.61M | 675.60M | 614.13M |
| Operating Income | 6.41M | -8.22M | 44.80M | 65.57M | 101.95M |
| Income Before Tax | 26.37M | 12.13M | 66.46M | 88.51M | 126.21M |
| Income Tax Expenses | -28.81M | -35.21M | -33.19M | -17.60M | -7.44M |
| Earnings from Continuing Operations | 55.18 | 47.34 | 99.65 | 106.11 | 133.66 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 55.18M | 47.34M | 99.65M | 106.11M | 133.66M |
| EBIT | 6.41M | -8.22M | 44.80M | 65.57M | 101.95M |
| EBITDA | 8.44M | -6.58M | 46.31M | 67.07M | 103.48M |
| EPS Basic | 0.52 | 0.45 | 0.94 | 1.01 | 1.27 |
| Normalized Basic EPS | 0.16 | 0.07 | 0.40 | 0.53 | 0.76 |
| EPS Diluted | 0.42 | 0.35 | 0.82 | 0.88 | 1.13 |
| Normalized Diluted EPS | 0.11 | 0.03 | 0.35 | 0.46 | 0.67 |
| Average Basic Shares Outstanding | 417.05M | 415.79M | 415.46M | 415.41M | 415.23M |
| Average Diluted Shares Outstanding | 462.11M | 464.21M | 479.60M | 478.20M | 472.49M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |